The activity of phosphohexose isomerase in primary breast carcinomas and response to chemotherapy in patients with metastatic disease.
The activity of phosphohexose isomerase [PHI] was measured in 48 primary carcinomas from patients with breast cancer, and its usefulness as a predictor of response to cytotoxic drugs at the metastatic stage was evaluated. There was a statistically significant difference in the activity of PHI between responders and non-responders to these treatments. These preliminary findings are currently being evaluated in an extended series.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000201:enzymology*; D005956:Glucose-6-Phosphate Isomerase / Q000378:metabolism*; D006801:Humans; D009362:Neoplasm Metastasis; D011379:Prognosis
D000970:Antineoplastic Agents; D005956:Glucose-6-Phosphate Isomerase